AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
10X Genomics Inc (NASDAQ:TXG)
32.16 USD
+1.450 4.722%Sponsored Reports
Loading...
| Previous Close (in USD) | 30.71 |
|---|---|
| Change | +1.450 4.722% |
| 52 W H/L (in USD) | 24.850/6.780 |
| EBITDA (in USD) | -146.882M |
| PE Ratio | -- |
| Volume | 3371245 |
| Diluted Eps TTM | -1.30 |
| Total Assets (in USD) | 918.636M |
|---|---|
| Total Liabilities (in USD) | 208.502M |
| Revenue TTM (in USD) | 624.662M |
| Cash (in USD) | 344.067M |
| Market Cap (in USD) | 1,156.228 M |
| Revenue Per Share TTM | 5.152 |
| Gross Profit TTM (in USD) | 427.013M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
10X Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588-3260
925 401 7300
Employees: 1306
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Serge Saxonov Ph.D. | Co-Founder, CEO & Director | 1977 |
| 2. | Dr. Benjamin J. Hindson Ph.D. | Co-Founder, Pres, Chief Scientific Officer & Director | 1975 |
| 3. | Mr. Justin J. McAnear | Chief Financial Officer | 1976 |
| 4. | Mr. Eric S. Whitaker Esq. | Chief Legal Officer | 1967 |
| 5. | Mr. Michael Schnall-Levin | Founding Scientist & CTO | NA |
| 6. | Ms. Cassie Corneau | Mang. of Investor Relations and Strategic Fin. | NA |
| 7. | Mr. Jonathan Schimmel | VP of Global Support & Sales Operations | NA |
| 8. | Ms. Rebecca Port | Chief People Officer | NA |
| 9. | Ms. Ruth De Backer | Chief Bus. Officer | 1977 |
| 10. | Mr. Jim Wilbur Ph.D. | Chief Commercial Officer | NA |
Peers
Sector: Healthcare
Industry: Health Information Services
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
VEEV
Veeva Systems Inc Class A |
-4.220 2.307% | 181.49 | 54.610 | 33.223 | 12.830 | 6.727 | 11.138 | 58.844 |
|
MTHRF
M3 Inc |
0.000 0.000% | 11 | 29.720 | 25.000 | 0.046 | 4.379 | 0.041 | 0.118 |
|
MTHRY
M3 Inc |
-0.064 1.341% | 4.75 | 31.840 | 26.247 | 0.047 | 4.597 | 0.041 | 0.118 |
|
BTSG
BrightSpring Health Services, Inc. Common Stock |
+1.540 2.595% | 59.83 | 100.220 | 40.650 | 0.690 | 4.925 | 0.918 | 25.797 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -161.971M | -53.715M | -534.476M | -31.033M | -112.398M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | -166M | -58.223M | -542.731M | -31.251M | -112.485M |
| Selling General Administrative | 298.3M | 257.56M | 202.326M | 130.834M | 87.936M |
| Gross Profit | 396.023M | 416.399M | 240.377M | 184.86M | 117.652M |
| Reconciled Depreciation | 33.006M | 28.254M | 19.021M | 7.066M | 3.905M |
| Ebit | -167.944M | -52.913M | -85.324M | -29.071M | -17.046M |
| Ebitda | -161.495M | -53.509M | -82.455M | -26.452M | -13.141M |
| Depreciation And Amortization | 6.449M | -0.596M | 2.869M | 2.619M | 3.905M |
| Operating Income | -167.944M | -52.913M | -85.324M | -29.071M | -110.764M |
| Other Operating Expenses | 684.353M | 543.403M | 384.169M | 274.964M | 164.134M |
| Interest Expense | 0.476M | 0.866M | 1.682M | 3.079M | 2.409M |
| Tax Provision | 4.029M | 4.508M | 8.255M | 0.218M | 0.087M |
| Interest Income | 6.647M | 0.206M | 1.532M | 2.805M | 1.024M |
| Net Interest Income | 6.171M | -0.66M | -0.15M | -0.274M | -1.385M |
| Income Tax Expense | 4.029M | 4.508M | 8.255M | 0.218M | 0.087M |
| Total Revenue | 516.409M | 490.49M | 298.845M | 245.893M | 146.313M |
| Total Operating Expenses | 563.967M | 469.312M | 325.701M | 213.931M | 135.473M |
| Cost Of Revenue | 120.386M | 74.091M | 58.468M | 61.033M | 28.661M |
| Total Other Income Expense Net | 5.973M | -0.802M | -449.152M | -1.962M | -93.192M |
| Net Income From Continuing Ops | -166M | -58.223M | -542.731M | -31.251M | -112.485M |
| Net Income Applicable To Common Shares | -166M | -58.223M | -542.731M | -31.251M | -112.485M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|---|
| Total Assets | 918.636M | 965.143M | 1028.98M | 1018.826M | 929.341M |
| Intangible Assets | 15.671M | 16.616M | 22.858M | 25.397M | 22.354M |
| Other Current Assets | 20.016M | 18.789M | 16.578M | 14.924M | 29.596M |
| Total Liab | 208.502M | 224.1M | 223.237M | 201.258M | 190.269M |
| Total Stockholder Equity | 710.134M | 741.043M | 805.743M | 817.568M | 739.072M |
| Other Current Liab | 64.908M | 86.753M | 92.454M | 82.535M | 103.009M |
| Common Stock | 0.002M | 0.002M | 0.002M | 0.002M | 0.002M |
| Capital Stock | 0.002M | 0.002M | 0.002M | 0.002M | 0.002M |
| Retained Earnings | -1467.047M | -1284.42M | -1029.321M | -863.321M | -805.098M |
| Good Will | 4.511M | 4.511M | 4.511M | 4.511M | - |
| Other Assets | - | - | 7.366M | 10.917M | 82.135M |
| Cash | 344.067M | 359.284M | 219.746M | 587.447M | 663.603M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 117.633M | 127.162M | 130.957M | 110.357M | 118.126M |
| Current Deferred Revenue | 20.658M | 13.15M | 7.867M | 5.34M | 4.472M |
| Net Debt | -261.454M | -263.914M | -124.57M | -505.469M | -600.625M |
| Short Term Debt | 9.286M | 11.521M | 9.037M | 5.131M | 5.936M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 82.613M | 95.37M | 95.176M | 81.978M | 62.978M |
| Other Stockholder Equity | 2177.672M | 2025.89M | 1839.397M | 1680.865M | 1544.218M |
| Property Plant Equipment | - | - | 289.328M | 230.41M | 72.84M |
| Total Current Assets | 584.387M | 596.022M | 635.035M | 747.591M | 774.366M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 49.335M | 29.411M | 210.238M | - | - |
| Net Receivables | 87.862M | 114.832M | 104.211M | 85.254M | 51.208M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 83.107M | 73.706M | 81.629M | 59.966M | 29.959M |
| Accounts Payable | 12.909M | 15.738M | 21.599M | 17.351M | 4.709M |
| Accumulated Other Comprehensive Income | -0.493M | -0.429M | -4.335M | 0.022M | -0.05M |
| Non Currrent Assets Other | 4.129M | 3.062M | 7.366M | 10.917M | 12.798M |
| Non Current Assets Total | 334.249M | 369.121M | 393.945M | 271.235M | 154.975M |
| Capital Lease Obligations | 82.613M | 95.37M | 95.176M | 81.978M | 62.978M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -350.887M | -106.729M | -38.394M | -42.767M | -6.709M |
| Total Cashflows From Investing Activities | -350.887M | -106.729M | -38.394M | -42.767M | -6.709M |
| Total Cash From Financing Activities | 15.817M | 35.297M | 468.906M | 414.59M | 105.367M |
| Net Income | -166M | -58.223M | -542.731M | -31.251M | -112.485M |
| Change In Cash | -368.72M | -92.571M | 212.151M | 406.405M | 22.231M |
| Begin Period Cash Flow | 596.073M | 688.644M | 476.493M | 70.088M | 47.857M |
| End Period Cash Flow | 227.353M | 596.073M | 688.644M | 476.493M | 70.088M |
| Total Cash From Operating Activities | -33.606M | -21.373M | -217.898M | 34.627M | -76.409M |
| Depreciation | 33.006M | 28.254M | 19.021M | 7.066M | 3.905M |
| Other Cashflows From Investing Activities | -4M | -5.451M | -1.728M | - | 0M |
| Dividends Paid | - | - | - | - | 0M |
| Change To Inventory | -21.192M | -30.132M | -14.601M | -6.699M | -3.732M |
| Sale Purchase Of Stock | 21.226M | 40.325M | 506.01M | 0M | 0M |
| Other Cashflows From Financing Activities | -5.409M | 35.297M | 17.895M | 14.766M | 104.342M |
| Capital Expenditures | 131.661M | 101.278M | 38.394M | 42.767M | 6.709M |
| Change In Working Capital | -39.417M | -87.445M | -50.381M | 44.764M | 28.015M |
| Other Non Cash Items | 1.957M | 0.079M | 306.017M | 0.101M | 1.247M |
| Free Cash Flow | -165.267M | -122.651M | -256.292M | -8.14M | -83.118M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | ARK Innovation ETF | 1 year ago | 8711149 |
| 2. | ARK Disruptive Innovation Full Composite | 1 year ago | 8667629 |
| 3. | ARK Genomic Revolution ETF | 1 year ago | 3240049 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 3182864 |
| 5. | Nikko AM ARK Disruptive Innovation A USD | 1 year ago | 3101620 |
| 6. | ARK Genomic Revolution | 1 year ago | 2965017 |
| 7. | Vanguard Small Cap Index | 1 year ago | 2583966 |
| 8. | Fidelity Growth Company Fund | 1 year ago | 2098286 |
| 9. | Nikko AM ARK Pstv Chg Innovt P JPY Acc | 1 year ago | 2006525 |
| 10. | UBS Lux Dgtl Hlth Eq Fd seeding P acc | 1 year ago | 2000000 |
| 11. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 1678270 |
| 12. | Fidelity Select Medical Tech and Devcs | 1 year ago | 1500000 |
| 13. | American Funds SMALLCAP World A | 1 year ago | 1452300 |
| 14. | Vanguard Small Cap Growth Index Inv | 1 year ago | 1437730 |
| 15. | Fidelity Select Health Care | 1 year ago | 1080000 |
| 16. | Strategic Advisers Fidelity US TtlStk | 1 year ago | 938000 |
| 17. | Vanguard Strategic Equity Inv | 1 year ago | 847843 |
| 18. | Fidelity Advisor Health Care I | 1 year ago | 800000 |
| 19. | Fidelity OTC | 1 year ago | 799366 |
| 20. | BlackRock Global Equity Mkt Netrl Instl | 1 year ago | 781446 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | ARK Investment Management LLC | 1 year ago | 12845713 |
| 2. | Vanguard Group Inc | 1 year ago | 11118086 |
| 3. | FMR Inc | 1 year ago | 9893139 |
| 4. | BlackRock Inc | 1 year ago | 6667822 |
| 5. | Sumitomo Mitsui Trust Group Inc | 1 year ago | 5363366 |
| 6. | Nikko Asset Management Americas Inc | 1 year ago | 5362656 |
| 7. | Morgan Stanley - Brokerage Accounts | 1 year ago | 3925271 |
| 8. | RA Capital Management, LLC | 1 year ago | 3279401 |
| 9. | UBS Asset Mgmt Americas Inc | 1 year ago | 2116573 |
| 10. | Citadel Advisors Llc | 1 year ago | 2006358 |
| 11. | Brown Capital Management, LLC | 1 year ago | 1843960 |
| 12. | Geode Capital Management, LLC | 1 year ago | 1814823 |
| 13. | State Street Corp | 1 year ago | 1812201 |
| 14. | T. Rowe Price Associates, Inc. | 1 year ago | 1781268 |
| 15. | Two Sigma Advisers, LLC | 1 year ago | 1744800 |
| 16. | Assenagon Asset Management SA | 1 year ago | 1734634 |
| 17. | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1 year ago | 1623675 |
| 18. | Deerfield Management Co | 1 year ago | 1503594 |
| 19. | Capital World Investors | 1 year ago | 1452300 |
| 20. | Two Sigma Investments LLC | 1 year ago | 1425205 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...